- Home
- PRZO vs KZIA Comparison
PRZO vs KZIA Comparison
Compare PRZO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- KZIA
- Stock Information
- Founded
- PRZO 2014
- KZIA 1994
- Country
- PRZO Israel
- KZIA Australia
- Employees
- PRZO N/A
- KZIA N/A
- Industry
- PRZO
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- KZIA Health Care
- Exchange
- PRZO Nasdaq
- KZIA Nasdaq
- Market Cap
- PRZO 7.8M
- KZIA 7.8M
- IPO Year
- PRZO 2023
- KZIA 1999
- Fundamental
- Price
- PRZO $1.66
- KZIA $1.29
- Analyst Decision
- PRZO
- KZIA Strong Buy
- Analyst Count
- PRZO 0
- KZIA 2
- Target Price
- PRZO N/A
- KZIA $11.50
- AVG Volume (30 Days)
- PRZO 4.3M
- KZIA 5.5M
- Earning Date
- PRZO 03-26-2025
- KZIA 03-26-2025
- Dividend Yield
- PRZO N/A
- KZIA N/A
- EPS Growth
- PRZO N/A
- KZIA N/A
- EPS
- PRZO N/A
- KZIA N/A
- Revenue
- PRZO $558,382.00
- KZIA $1,655,324.00
- Revenue This Year
- PRZO N/A
- KZIA $806.89
- Revenue Next Year
- PRZO N/A
- KZIA N/A
- P/E Ratio
- PRZO N/A
- KZIA N/A
- Revenue Growth
- PRZO N/A
- KZIA 248000.00
- 52 Week Low
- PRZO $0.49
- KZIA $1.25
- 52 Week High
- PRZO $3.16
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PRZO 47.25
- KZIA 39.50
- Support Level
- PRZO $1.71
- KZIA $1.31
- Resistance Level
- PRZO $1.77
- KZIA $2.64
- Average True Range (ATR)
- PRZO 0.12
- KZIA 0.24
- MACD
- PRZO -0.03
- KZIA 0.09
- Stochastic Oscillator
- PRZO 34.67
- KZIA 14.29
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the comapany applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.